Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

772
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
772
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

901
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
901
Glaucoma: Overview01:25

Glaucoma: Overview

1.0K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.0K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

287
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
287
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

294
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
294
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.9K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discontinuing Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration That Remains Inactive with Treatment at the Maximum Injection Interval.

Clinical ophthalmology (Auckland, N.Z.)·2026
Same author

Assessing Polypoidal Choroidal Vasculopathy-Related OCT Features in the TENAYA and LUCERNE Trials.

Ophthalmology science·2026
Same author

Advances in Polypoidal Choroidal Vasculopathy (PCV) Management: Emerging Evidence for Faricimab and Aflibercept 8 mg.

Ophthalmology and therapy·2026
Same author

Aflibercept With vs Without Reduced-Fluence Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: Optical Coherence Tomography Angiographic changes from a randomized clinical trial.

American journal of ophthalmology·2026
Same author

Fluorescein Angiography Leakage Patterns in Pachychoroid Neovasculopathy: Neovascularization or Central Serous Chorioretinopathy?

Ophthalmology and therapy·2026
Same author

Predictors of 1-Year Visual Outcome in Central-Involving Submacular Hemorrhage Secondary to Neovascular AMD.

American journal of ophthalmology·2026
Same journal

Determinants of regression kinetics in observed stage 3 retinopathy of prematurity without plus disease.

Eye (London, England)·2026
Same journal

Oculomics and the NHS: A UK opportunity to translate eye-derived biomarkers into population health.

Eye (London, England)·2026
Same journal

Long-term follow-up and outcomes of a Diabetic Eye Screening Programme in patients aged 80 with no diabetic eye disease at baseline: should we be routinely screening this cohort?

Eye (London, England)·2026
Same journal

Real world experience with faricimab in switched neovascular AMD and evaluation of reloading versus interval matching regimes.

Eye (London, England)·2026
Same journal

"When the lens drew a continent: a cartographic clue to Alport syndrome".

Eye (London, England)·2026
Same journal

Infographic: efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity.

Eye (London, England)·2026
See all related articles

Related Experiment Video

Updated: Oct 28, 2025

Detecting Abnormalities in Choroidal Vasculature in a Mouse Model of Age-related Macular Degeneration by Time-course Indocyanine Green Angiography
10:24

Detecting Abnormalities in Choroidal Vasculature in a Mouse Model of Age-related Macular Degeneration by Time-course Indocyanine Green Angiography

Published on: February 19, 2014

13.8K

Evolving treatment paradigms for PCV.

Beau J Fenner1,2, Chui Ming Gemmy Cheung1,2, Shaun S Sim1

  • 1Singapore National Eye Centre and Singapore Eye Research Institute, Singapore, Singapore.

Eye (London, England)
|July 15, 2021
PubMed
Summary
This summary is machine-generated.

Polypoidal choroidal vasculopathy (PCV), a form of wet age-related macular degeneration, requires tailored treatments. Research explores new therapies and imaging to improve outcomes and reduce patient treatment burden.

More Related Videos

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model
09:56

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model

Published on: January 21, 2018

9.5K
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.3K

Related Experiment Videos

Last Updated: Oct 28, 2025

Detecting Abnormalities in Choroidal Vasculature in a Mouse Model of Age-related Macular Degeneration by Time-course Indocyanine Green Angiography
10:24

Detecting Abnormalities in Choroidal Vasculature in a Mouse Model of Age-related Macular Degeneration by Time-course Indocyanine Green Angiography

Published on: February 19, 2014

13.8K
In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model
09:56

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model

Published on: January 21, 2018

9.5K
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.3K

Area of Science:

  • Ophthalmology
  • Medical Research

Background:

  • Polypoidal choroidal vasculopathy (PCV) is a significant subtype of neovascular age-related macular degeneration (nAMD), prevalent globally, especially in Asia.
  • Current PCV management often mirrors typical nAMD treatments, but knowledge gaps persist regarding optimal strategies and their appropriateness for PCV.

Purpose of the Study:

  • To review current polypoidal choroidal vasculopathy management.
  • To explore emerging treatment approaches for PCV based on enhanced understanding of its pathophysiology.

Main Methods:

  • Review of current clinical trial data on anti-vascular endothelial growth factor (VEGF) therapy and photodynamic therapy for PCV.
  • Analysis of advancements in imaging modalities like OCT angiography for PCV biomarker identification.
  • Exploration of new therapeutic avenues targeting choroidal anatomy and lipid mediators.

Main Results:

  • Intravitreal anti-VEGF therapy, alone or combined with photodynamic therapy, shows efficacy in managing PCV symptoms.
  • Novel imaging techniques aid in characterizing PCV biomarkers, potentially guiding treatment initiation and intervals.
  • Emerging anti-VEGF agents and drug delivery systems aim to reduce treatment burden.

Conclusions:

  • Optimizing treatment intervals and exploring novel therapies are crucial for effective PCV management.
  • Understanding PCV pathophysiology offers new avenues for treatment beyond current anti-VEGF strategies.
  • Future research focuses on reducing treatment burden and improving long-term outcomes for PCV patients.